Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Retained Earnings: 2017-2024

Historic Retained Earnings for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to -$611.3 million.

  • Cidara Therapeutics' Retained Earnings fell 33.04% to -$743.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$743.7 million, marking a year-over-year decrease of 33.04%. This contributed to the annual value of -$611.3 million for FY2024, which is 38.47% down from last year.
  • Per Cidara Therapeutics' latest filing, its Retained Earnings stood at -$611.3 million for FY2024, which was down 38.47% from -$441.4 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' Retained Earnings ranged from a high of -$334.7 million in FY2020 and a low of -$611.3 million during FY2024.
  • For the 3-year period, Cidara Therapeutics' Retained Earnings averaged around -$490.4 million, with its median value being -$441.4 million (2023).
  • Data for Cidara Therapeutics' Retained Earnings shows a maximum YoY plummeted of 38.47% (in 2024) over the last 5 years.
  • Over the past 5 years, Cidara Therapeutics' Retained Earnings (Yearly) stood at -$334.7 million in 2020, then fell by 12.69% to -$377.2 million in 2021, then decreased by 10.96% to -$418.5 million in 2022, then dropped by 5.48% to -$441.4 million in 2023, then plummeted by 38.47% to -$611.3 million in 2024.